ARCHIVES

Funding Exceptions, Skipovers, While Limited At NCI, Become Crucial Issues; NCAB To Be Brief On Details

This article is from The Cancer Letter archive.

Vol. 09 No. 01 | January 7, 1983

Download PDF Visit The Full Archive

Related Articles

NCI Budget for FY 1977 Would Halt New Research

January 23, 1976

Appropriations: Senate Committee Approves 4.5 Percent Cut To Defense Dept. Cancer Research Funding

July 25, 2014

FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI

April 15, 1977

Clinical Trials Approved By NCI In November

December 28, 2001

Celebrex Studies Show Polyp Reduction, Point To Challenges In Biomarker Validation

April 28, 2006

Tasigna Wins New Indication For CML; Jevtana Approved For Prostate Cancer

June 18, 2010